{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:32:59Z","timestamp":1782491579270,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014101","name":"Novavax Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126777","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T05:18:17Z","timestamp":1738300697000},"page":"126777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review"],"prefix":"10.1016","volume":"49","author":[{"given":"Manuela H.","family":"Gschwend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Poelaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Rousculp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Caldera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126777_bb0010","series-title":"Immunodeficiency. NCBI Bookshelf StatPearls","author":"Justiz Vaillant","year":"2023"},{"key":"10.1016\/j.vaccine.2025.126777_bb0015","article-title":"Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126777_bb0020","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s12325-023-02754-0","article-title":"Assessing the burden and cost of COVID-19 across variants in commercially insured immunocompromised populations in the United States: updated results and trends from the ongoing EPOCH-US study","volume":"41","author":"Ketkar","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2025.126777_bb0030","article-title":"COVID-19 hospitalisations in immunocompromised individuals in the omicron era: a population-based observational study using surveillance data in British Columbia","volume":"20","author":"Bahremand","year":"2023","journal-title":"Canada Lancet Reg Health Am"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126777_bb0035","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2214-109X(21)00593-3","article-title":"Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review","volume":"10","author":"Parker","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.126777_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","volume":"59","author":"Shoham","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126777_bb0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.vaccine.2025.126777_bb0050","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126777_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041451","article-title":"Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen","volume":"7","author":"Reimer","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126777_bb0070","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40520-023-02380-4","article-title":"Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic","volume":"35","author":"Bukan","year":"2023","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126777_bb0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2025.126777_bb0080","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126777_bb0085","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40121-024-00936-z","article-title":"Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: systematic literature review and Meta-analysis using the GRADE framework","volume":"13","author":"Kavikondala","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2025.126777_bb0090","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126777_bb0095","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s40121-024-01005-1","article-title":"Real-world effectiveness of a third dose of mRNA-1273 versus BNT162b2 on inpatient and medically attended COVID-19 among immunocompromised US adults","volume":"13","author":"Sun","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126777_bb0105","article-title":"Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI","volume":"4","author":"Korencak","year":"2019","journal-title":"Insight"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126777_bb0110","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3018(22)00041-8","article-title":"Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A\/2B trial","volume":"9","author":"Madhi","year":"2022","journal-title":"Lancet HIV"},{"issue":"20","key":"10.1016\/j.vaccine.2025.126777_bb0115","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126777_bb0120","article-title":"Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in south African people living with and without HIV-1 infection: a phase 2 randomised trial","volume":"89","author":"Bennett","year":"2024","journal-title":"J Inf Secur"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126777_bb0125","first-page":"334","article-title":"Current and future immunotherapies for multiple sclerosis","volume":"118","author":"Bourque","year":"2021","journal-title":"Mo Med"},{"key":"10.1016\/j.vaccine.2025.126777_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104102","article-title":"Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: a meta-analysis","volume":"81","author":"Wu","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.126777_bb0135","doi-asserted-by":"crossref","first-page":"1081933","DOI":"10.3389\/fimmu.2023.1081933","article-title":"NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines","volume":"14","author":"Mueller-Enz","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126777_bb0140","article-title":"SARS-CoV-2-specific immune cytokine profiles to mRNA, viral vector and protein-based vaccines in patients with multiple sclerosis: beyond interferon gamma","volume":"12","author":"Al Rahbani","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126777_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210301","article-title":"Current status regarding immunosuppressive treatment in patients after renal transplantation","volume":"24","author":"Szumilas","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126777_bb0150","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/cid\/ciaa1897","article-title":"Immunogenicity and safety of the 9-valent human papillomavirus vaccine in solid organ transplant recipients and adults infected with human immunodeficiency virus (HIV)","volume":"73","author":"Boey","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126777_bb0155","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.2215\/CJN.02160311","article-title":"Efficacy of influenza a H1N1\/2009 vaccine in hemodialysis and kidney transplant patients","volume":"6","author":"Crespo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126777_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126777_bb0165","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/ndt\/gfad010","article-title":"Serological response to Nuvaxovid (NVX-CoV2373) vaccine given as a fifth dose in non- and low-responder kidney transplant recipients","volume":"38","author":"Nowak","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126777_bb0170","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s43018-020-0104-9","article-title":"SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer","volume":"1","author":"Rugge","year":"2020","journal-title":"Nat Can"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126777_bb0175","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s15010-023-02125-5","article-title":"Early combination therapy of COVID-19 in high-risk patients","volume":"52","author":"Orth","year":"2024","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126777_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.31662\/jmaj.2023-0171","article-title":"Efficacy of COVID-19 vaccines in patients with hematological malignancy compared to healthy controls: a systematic review and Meta-analysis","volume":"7","author":"Das Barshan","year":"2024","journal-title":"JMA J"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126777_bb0185","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(24)00065-1","article-title":"Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"6","author":"Goodyear","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"22","key":"10.1016\/j.vaccine.2025.126777_bb0190","doi-asserted-by":"crossref","first-page":"126054","DOI":"10.1016\/j.vaccine.2024.05.081","article-title":"Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series","volume":"42","author":"Sherman","year":"2024","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126777_bb0195","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/cid\/ciae192","article-title":"COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials","volume":"79","author":"Sherman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126777_bb0200","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.42030","article-title":"SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and Meta-analysis","volume":"74","author":"Conway","year":"2022","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126777_bb0205","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.41619","article-title":"COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter","volume":"73","author":"D\u2019Silva","year":"2021","journal-title":"Comparative Cohort Study Arthritis Rheumatol"},{"key":"10.1016\/j.vaccine.2025.126777_bb0210","series-title":"Pharmacotherapy in systemic rheumatic diseases. In: Almoallim H, Cheikh M, editors. Skills in rheumatology. Singapore","author":"Borham","year":"2021"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126777_bb0215","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.41734","article-title":"American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 1","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126777_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-002998","article-title":"Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases","volume":"9","author":"Hasseli","year":"2023","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126777_bb0225","first-page":"593","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.126777_bb0230","doi-asserted-by":"crossref","first-page":"A15","DOI":"10.1016\/j.vaccine.2020.11.037","article-title":"Influenza vaccination in immunocompromised populations: strategies to improve immunogenicity","volume":"39","author":"Caldera","year":"2021","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2025.126777_bb0235","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1469-0691.2012.03971.x","article-title":"Vaccination of immunocompromised patients","volume":"18","author":"Ljungman","year":"2012","journal-title":"Clin Microbiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:18:47Z","timestamp":1741346327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"alternative-id":["S0264410X2500074X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126777","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126777"}}